Launched Niagen(TM) Plus Niagen(TM) Liquid At-Home Injections

Launched Niagen NanoCloud(TM), the first dermatologist-tested topical product

Launched "Don't Get Old. Age Better.(R)," a new brand campaign

Net sales of $27.2 million, including $23.3 million from Tru Niagen

Generated $2.6 million of operating cash flow

LOS ANGELES--(BUSINESS WIRE)--November 04, 2026-- 

Niagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced its operational updates and financial results for the third quarter of 2026.

Third Quarter 2026 Financial and Business Highlights

   --  Total net sales of $27.2 million, including $23.3 million from Tru 
      Niagen(R). Direct to consumer sales on the Company's website grew by 13% 
      year-over-year. 
 
   --  Gross margin of 62.9%, which the Company believes reflects the strength 
      of its operational foundation. 
 
   --  Net loss of $1.2 million, with basic and diluted loss per share of 
      $(0.01). 
 
   --  Adjusted EBITDA, a non-GAAP measure, was positive at $0.5 million. 
 
   --  Total cash provided by operations of $4.2 million during the nine 
      months ended September 30, 2026, and $2.6 million in the three-month 
      period. 
 
   --  The Company ended the quarter with $69.5 million in cash and cash 
      equivalents, as compared to $66.7 million in cash and cash equivalents 
      for the period ended June 30, 2026. 
 
   --  Launched the liquid, ready-to-inject Niagen(TM) At-Home Injection Kit, 
      formulated with pharmaceutical grade Niagen nicotinamide riboside (NR) 
      through the Niagen(TM) Plus telehealth platform. 
 
   --  Launched Tru Niagen(R) Skincare, a permanent new category in the core 
      Tru Niagen line. The inaugural product in this new category is Niagen 
      NanoCloud(TM), the first dermatologist-tested topical product powered by 
      Niagen NR. 
 
   --  Launched "Don't Get Old. Age Better(R)," a new brand campaign for the 
      Niagen(R) brand and sub-brands Tru Niagen(R) and Niagen Plus(TM), 
      featuring 11-time world champion surfer Kelly Slater and more than 20 
      partners, across sports, entertainment, and medicine. 
 
   --  Announced a Start-Up Agreement with Mass General Brigham (MGB) to begin 
      detailed planning for what is envisioned to be the largest and most 
      comprehensive clinical trial of Niagen to date. 
 
   --  NAD Pharmaceuticals engaged Red Sky Partners, a life sciences strategic 
      advisory firm, to support the advancement of NB4168, the Company's small 
      molecule investigational drug candidate, targeting rare genetic diseases 
      and aging-related disorders. 
 
   --  Expanded access to Tru Niagen by launching on Walmart.com and 
      diversified the e-commerce marketplace presence and expanded retail 
      footprint by launching at nearly 300 GNC and Sam's Club locations across 
      44 states combined. 
 
   --  Announced the publication of a new peer-reviewed analysis of past 
      clinical studies in Aging Cell examining the effects of Niagen(R) 
      supplementation was associated with reduced muscle epigenetic age 
      acceleration measured by the Muscle Epigenetic Age Test (MEAT) clock. 

"During the third quarter, we navigated near-term commercial headwinds while continuing to generate positive adjusted EBITDA and $2.6 million in operating cash flow and make tangible progress across the Niagen platform," said Rob Fried, Chief Executive Officer. "We advanced NB4168, expanded Tru Niagen distribution, established skincare as a permanent category, launched a more convenient ready-to-inject Niagen Plus product, and invested in brand awareness and long-term clinical research. As stated before, we view 2026 as an investment year, and believe the progress we are making across consumer health, ingredients, injectables, skincare, and pharmaceuticals provides a strong springboard for meaningful growth in 2027 and beyond."

2026 Outlook and Strategic Priorities:

For the full year 2026, the Company expects direct website revenues to grow by 15% to 20% year-over-year and overall e-commerce to grow by approximately 5% year-over-year. The Company expects the performance of the remainder of its consumer business to offset the growth of the e-commerce business. The ingredient business is expected to be lower than the prior year, primarily due to decreased volume from key ingredient partners due to competitive market dynamics, although additional ingredient partners were added in Q3 2026 and more are expected to be added in the near term. The Company is planning to introduce a lower-cost NR salt form, patented by Niagen Bioscience, which is expected to reduce cost of goods sold and strengthen the ingredient business. The Company expects Niagen Plus growth and new skincare partnerships to become meaningful contributors beginning in 2027.

The Company believes 2026 is an important year of strategic investment and continues to expect operating expenses to increase as it invests across commercial, research and administrative functions to support these strategic priorities, while continuing to focus on disciplined capital allocation and positive cash flow from operations.

Investor Conference Call

A live webcast will be held Wednesday, November 4, 2026 at 4:30 p.m. Eastern Standard Time (1:30 p.m. Pacific Standard Time) to discuss Niagen Bioscience's third-quarter financial results and provide a general business update.

To listen to the webcast, or to view the earnings press release and its accompanying financial exhibits, please visit the Investor Relations section of Niagen Bioscience's website at https://investors.niagenbioscience.com. The toll-free dial-in information for this call is 1-833-461-5787 with Conference ID: 198389474. The webcast will be recorded, and will be available for replay via the website from 7:30 p.m. Eastern Standard Time on November 4, 2026.

Important Note on Forward-Looking Statements:

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects," "anticipates," "intends," "estimates," "plans," "potential," "possible," "probable," "believes," "seeks," "may," "will," "should," "could," "predicts," "projects," "continues," "would" or the negative of such terms or other similar expressions. Forward-looking statements include without limitation, statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the quotation from Niagen Bioscience's Chief Executive Officer, statements related to the Company's 2026 financial outlook including but not limited to net sales, gross margin, expenses, investment priorities, and commercialization efforts and statements regarding Niagen(R) and Niagen Plus clinical initiatives and statements attributable to management.

Risks that contribute to the uncertain nature of the forward-looking statements include: our relationships with major customers; a decline in general economic conditions nationally and internationally; the market and size of the vitamin, mineral and dietary supplement market and the intravenous market; decreased demand for our products and services; market acceptance of our products; the success of our brand campaign and other marketing investments; interruptions in our ability to sell products through third-party online marketplaces; the ability to protect our intellectual property rights; impact of any litigation or infringement actions brought against us; regulation of our advertising, marketing and sales practices by the FTC and state authorities; competition from other providers and products, including other supplements such as NMN; risks in product development; our ability to develop pharmaceutical business; the Company's therapeutic pipeline, including NB4168, preclinical and IND-enabling studies, and regulatory designations and development plans; inability to raise capital to fund continuing operations or new product development; changes in government regulation or regulatory priorities of government officials; the ability to complete customer transactions and capital raising transactions; inflationary conditions and adverse economic conditions; our history of operating losses; the growth and profitability of our product sales; our ability to maintain and grow sales, marketing and distribution capabilities; changing consumer perceptions of our products; our reliance on a single or limited number of third-party suppliers; risks of conducting business in China; unanticipated developments in and risks related to the Company's ability to secure adequate quantities of pharmaceutical-grade Niagen in a timely manner; the Company's ability to obtain appropriate contracts and arrangements with U.S. FDA-registered 503B outsourcing facilities required to compound and distribute pharmaceutical-grade Niagen to clinics; the Company's ability to remain on the U.S. FDA Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act Category 1 list; the Company's ability to maintain and enforce the Company's existing intellectual property and obtain new patents; whether the potential benefits of NRC can be further supported; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials; determinations made by the FDA and other governmental authorities, including with respect to products seeking to compete in our market; mislabeling or other misleading marketing practices by competitors; economic and market instability,